Literature DB >> 10333125

N-acetylaspartylglutamate in Canavan disease: an adverse effector?

A P Burlina1, V Ferrari, P Divry, W Gradowska, C Jakobs, M J Bennett, A C Sewell, C Dionisi-Vici, A B Burlina.   

Abstract

UNLABELLED: We measured N-acetylaspartate and its precursor/product N-acetylaspartylglutamate (NAAG) in urine of patients with Canavan disease using capillary zone electrophoresis. Abnormal levels of NAAG were found in 32 of 43 patients examined. Elevated NAAG was also present in the CSF of one patient. Given that NAAG may interfere with N-methyl-D-aspartate receptor function, the occurrence of high levels of NAAG in patients' urine conceivably represents a participating factor in the pathogenesis of Canavan disease.
CONCLUSION: The biochemical role of N-acetylaspartylglutamate and its relationship to glutamatergic function may be relevant to the pathogenesis of Canavan disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10333125     DOI: 10.1007/s004310051102

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Molecular characterization of N-acetylaspartylglutamate synthetase.

Authors:  Ivonne Becker; Julia Lodder; Volkmar Gieselmann; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

Review 3.  MR spectroscopy: a powerful tool for investigating brain function and neurological diseases.

Authors:  A P Burlina; T Aureli; F Bracco; F Conti; L Battistin
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

4.  Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.

Authors:  Fanny Mochel; Nadège Boildieu; Julie Barritault; Catherine Sarret; Eleonore Eymard-Pierre; François Seguin; Raphael Schiffmann; Odile Boespflug-Tanguy
Journal:  Biochim Biophys Acta       Date:  2010-07-13

5.  Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats.

Authors:  Carolina Didonet Pederzolli; Francieli Juliana Rockenbach; Fernanda Rech Zanin; Nicoli Taiana Henn; Eline Coan Romagna; Angela M Sgaravatti; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Angela de Mattos Dutra; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

6.  Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseases.

Authors:  F Mochel; U F H Engelke; J Barritault; B Yang; N H McNeill; J N Thompson; A Vanderver; N I Wolf; M A Willemsen; F W Verheijen; F Seguin; R A Wevers; R Schiffmann
Journal:  Neurology       Date:  2010-01-26       Impact factor: 9.910

Review 7.  Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.

Authors:  M H Baslow
Journal:  J Mol Neurosci       Date:  2000-10       Impact factor: 2.866

8.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.

Authors:  Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  Front Mol Neurosci       Date:  2017-06-02       Impact factor: 5.639

9.  The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes.

Authors:  Karolina Kolodziejczyk; Nicola B Hamilton; Anna Wade; Ragnhildur Káradóttir; David Attwell
Journal:  Brain       Date:  2009-04-21       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.